Manufacturing News and Research

RSS

Manufacturing is the production of products across all industries, on a large-scale, using machinery.

Sinovac Dalian JV to research, develop, produce and commercialize human-use vaccines

Sinovac Biotech Ltd. ( SVA), a leading developer and provider of vaccines, announced today that it executed a joint venture (JV) agreement to establish Sinovac (Dalian) Vaccine Technology Co., Ltd. (Sinovac Dalian). The JV will research, develop, produce and commercialize human-use vaccines. Sinovac will contribute its expertise and experience in developing and commercializing world-class vaccines; the other party will bring its land use rights, manufacturing facilities and established operating infrastructure.

25 Nov 2009

Human Genome Sciences submits BLA for ZALBIN

Human Genome Sciences, Inc. today announced that it has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for ZALBIN™ (albinterferon alfa-2b) for the treatment of chronic hepatitis C. The BLA submission includes the results of two pivotal Phase 3 clinical trials showing that 900-mcg albinterferon alfa-2b dosed every two weeks met its primary endpoint of non-inferiority to peginterferon alfa-2a (Pegasys) dosed once each week.

25 Nov 2009

Comparative study of antioxidant contents in chocolate and cocoa-containing products in the U.S.

A recent study confirms that the antioxidants and other plant-based nutrients in chocolate and cocoa products are highly associated with the amount of non-fat cocoa-derived ingredients in the product. The study expands on previously published results.

25 Nov 2009

NIPTE to develop educational programs on leading edge pharmaceutical technology for FDA reviewers

The U.S. Food and Drug Administration (FDA) has awarded the National Institute for Pharmaceutical Technology and Education, Inc. (NIPTE) a $652,000 two-year contract to develop and deliver a professional development program to help to ensure that FDA reviewers are current in state-of-the-art pharmaceutical manufacturing and technology.

25 Nov 2009

Third-quarter financial results announced by SemBioSys Genetics

SemBioSys Genetics Inc., specializing in the manufacture of high-value proteins and oils in plant seeds, today announced its third quarter 2009 financial and operational results.

25 Nov 2009

Wellcore announces leadership team and product introduction plans

Wellcore Corporation, a Silicon Valley-based company dedicated to developing wireless products and services that promote wellness, safety and security, is announcing its leadership team and product introduction plans.

25 Nov 2009

First-quarter fiscal 2010 results announced by China Aoxing Pharmaceutical

China Aoxing Pharmaceutical Company, Inc., a China-based pharmaceutical company specializing in research, development, manufacturing and distribution of narcotic and pain-management products, today announced financial and operational results for the three month ended September 30, 2009, or the first quarter of fiscal year 2010.

24 Nov 2009

'Best New Elliptical' award for LifeSpan EL3000i elliptical trainer

New compact LifeSpan Elliptical Trainers, made by PCE Health and Fitness (www.lifespanfitness.com), were highly rated in annual fitness equipment reviews of best treadmills and elliptical trainers for 2010.

24 Nov 2009

Update from GeckoSystems regarding its CareBot elder care robot

GeckoSystems Intl. Corp. announced today that since their first annual "Mobile Robots in Motion" conference earlier this month, they have been solicited by another first tier contract manufacturer interested in the high volume manufacture of their product line. GeckoSystems is a dynamic leader in the emerging Mobile Service Robot industry revolutionizing their development and usage with "Mobile Robot Solutions for Safety, Security and Service™."

24 Nov 2009

Financial results for the third-quarter reported by China Biologic Products

China Biologic Products, Inc. ("China Biologic," or the "Company"), one of the leading plasma-based biopharmaceutical companies in the People's Republic of China ("PRC"), operating through its indirect majority- owned subsidiaries, Shandong Taibang Biological Products Co. Ltd. ("Taibang") and Guiyang Dalin Biologic Technologies Co., Ltd. ("Dalin") and its equity investment in Xi'an Huitian Blood Products Co., Ltd. ("Huitian"), today reported financial results for the third quarter ended September 30, 2009.

24 Nov 2009

Andor Technology reports 2009 preliminary results

ANDOR TECHNOLOGY PLC ("Andor") Preliminary Results for the year ended 30 September 2009 24 November 2009 Andor Technology plc (AND.L), the leading developer and manufacturer of high performance digital cameras and solutions for academic, industrial and government applications globally, today announces preliminary results for the year ended 30 September 2009.

24 Nov 2009

Clavis Pharma signs drug development and commercialisation agreement with Clovis Oncology

Clavis Pharma ASA, the clinical stage oncology focused pharmaceutical company, and Clovis Oncology, Inc., the newly formed oncology company led by former Pharmion Corporation executives, announced today an agreement for the further development and commercialisation of the Clavis Pharma drug candidate, CP-4126, currently in Phase II development in pancreatic cancer.

24 Nov 2009

PX’Therapeutics sets up additional biomanufacturing unit

PX’Therapeutics SA (formerly known as Protein’eXpert) announces the set up of an additional biomanufacturing unit dedicated to the production of therapeutic proteins and monoclonal antibodies in mammalian cells.

24 Nov 2009

AmKor and Hengdian Group sign license agreement to develop and market new drug candidate in China

AmKor (AmKor Pharma, Inc.) and Hengdian Group (Hengdian Group Ltd) today announced the signing of licensing agreement for further development and commercialization of Neu2000 in China.

24 Nov 2009

MedPro Safety Products updates on its recent progress

MedPro Safety Products, Inc., a pioneer in the development and marketing of passive needlestick injury prevention technology, today reported on the Company’s recent progress.

23 Nov 2009

Millipore completes acquisition of the remaining 60% ownership of its joint-venture in India

Millipore Corporation (NYSE:MIL), a leading provider of technologies, tools and services for the global life science industry, today announced it has acquired the remaining 60 percent ownership of its joint-venture in India, Millipore India Pvt. Ltd. The new subsidiary will enable Millipore to invest in initiatives that will drive growth and expand its leadership in India’s thriving life science market.

23 Nov 2009

Evidence does not connect H1N1 vaccine to patient deaths, WHO says

The deaths of 41 people from six countries who had received the H1N1 (swine flu) vaccine were not directly linked to the vaccine, the WHO said Thursday, the Associated Press/MSNBC reports (11/19).

20 Nov 2009

Impax Laboratories implements IBM's business analytics technology

IBM announced today that Impax Laboratories, Inc., a technology-based specialty pharmaceutical company, is using IBM business analytics technology to gain stronger insights into their business and better predict risks and market opportunities.

20 Nov 2009

FDA acknowledges Dendreon's amended BLA for PROVENGE as a complete response

Dendreon Corporation today announced that the U.S. Food and Drug Administration (FDA) provided written acknowledgement that the Company's amended Biologics License Application (BLA) for PROVENGE® (sipuleucel-T) is a complete response. The FDA has assigned a Prescription Drug User Fee Act (PDUFA) date of May 1, 2010, by which time it will respond to Dendreon's amended BLA. Dendreon is seeking licensure for PROVENGE for men with metastatic castrate-resistant prostate cancer (CRPC).

20 Nov 2009

Soligenix receives $9.4M NIAID grant to develop technology for advancing rapidly acting vaccines

Soligenix, Inc., formerly known as DOR BioPharma, Inc., a late-stage biotechnology company, announced today that it has formed a consortium to develop thermostable technology to advance RiVax(TM) and other rapidly acting vaccines. Soligenix received a $9.4 million grant from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH), to support this work.

20 Nov 2009